Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Evgen Pharma ( (GB:TCF) ) has provided an update.
TheraCryf plc has appointed Dr. Alastair Smith as the Non-executive Chair, following the passing of former Chair Dr. Sue Foden. Dr. Smith, a seasoned life sciences executive, brings over 20 years of experience in public company growth and strategy, notably leading Avacta Group plc to prominence. His appointment is seen as a strong endorsement of TheraCryf’s product portfolio, which includes promising assets in areas of high unmet need, such as the Orexin-1 antagonist candidate for addictive disorders. This strategic move occurs as TheraCryf prepares to advance its Orexin-1 program to clinical readiness, marking a potential significant value inflection point for the company.
More about Evgen Pharma
TheraCryf plc is a clinical-stage drug development company focusing on oncology and neuropsychiatry, with a diverse pipeline addressing glioblastoma, neurodevelopmental disorders, addiction, anxiety, and narcolepsy. The company aims to generate compelling data for preclinical and clinical proof of concept to partner with mid-size to large pharmaceutical firms for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and operates from its headquarters in Alderley Park, Cheshire. It is listed on AIM in London under the ticker TCF.
YTD Price Performance: 92.31%
Average Trading Volume: 946,368
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £4.3M
Learn more about TCF stock on TipRanks’ Stock Analysis page.
